Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971243 | 0.74 | — | — | |
| SCHEMBL3308694 | 0.69 | IDO1 (0.55) | L3MBTL1GAARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL8404472 | 0.69 | — | — | |
| SCHEMBL12472536 | 0.67 | — | — | |
| SCHEMBL2399343 | 0.67 | — | — | |
| SCHEMBL29105512 | 0.67 | — | — | |
| SCHEMBL173611 | 0.67 | GAA (0.62) | LMNAMAPTKDM4EHTTNPSR1 | |
| SCHEMBL19175733 | 0.66 | IDO1 (0.46) | LMNAMAPTRAB9ACYP3A4ALDH1A1 | |
| SCHEMBL1473281 | 0.66 | TDP1 (0.56) | LMNAHTTCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL18666717 | 0.65 | CHRM5 (0.37) | LMNAMAPTKDM4ECYP3A4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4617262-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyoto University (JP) | 2025-09-17 | — | — | EP | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3562822-B1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-03-05 | — | — | US | disclosed |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-03-05 | — | — | US | disclosed |
| EP-3562822-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Mitobridge, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-110167926-A | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | 米托布里奇公司 | 2019-08-23 | — | — | CN | disclosed |
| WO-2018125961-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | LMNA 172/4885MAPT 529/4885KDM4E 2486/4885 |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | LMNA 1783/4885MAPT 4593/4885KDM4E 427/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | LMNA 172/4885MAPT 529/4885KDM4E 2486/4885 |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | LMNA 172/4885MAPT 529/4885KDM4E 2486/4885 |
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | LMNA 3831/4885MAPT 1448/4885KDM4E 2891/4885 |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | LMNA 172/4885MAPT 529/4885KDM4E 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.